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ABSTRACT
Key Words:
Immunotherapy is a novel approach for the treatment of systemic malignancies. Passive and adaptive 
immunotherapy have been applied to the treatment of a wide variety of solid tumors such as malignant 
melanoma (1), renal cell carcinoma (2) and ovarian cancer (3). Several early clinical trials of immune based 
therapy for both non-small (NSCLC) and small cell lung cancer (SCLC) have demonstrated limited or no 
success (3,4) but recent trials of antigen-specific cancer immunotherapy have shown early therapeutic potential 
and are now being rigorously evaluated on a larger scale (5). In this communication we briefly review the 
historic aspects of immune based therapy for solid cancer, describe therapeutic strategies aimed at targeting 
lung cancer, and discuss limitations of current therapy and future directions of this field.
lung cancer; immunotherapy
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Does the immune system influence 
the development and progression of 
cancer?
Clinical data from immunosuppressed organ transplant recipients 
or patients with HIV clearly demonstrates an increase in viral 
mediated cancers such as cervical carcinoma (Human Papilloma 
Virus), hepatocellular carcinoma (Hepatitis B and C), as well 
as Burkitt’s Lymphoma (Epstein Barr Virus) (6-8). While such 
data maybe understandable in light of the defined role that the 
immune system plays in elimination of oncogenic viruses, large 
population based studies of solid organ transplant recipients 
also demonstrate an increase in multiple types of malignancies 
with no known viral etiology, such as malignant melanoma, 
renal cell carcinoma and non-Burkitt’s lymphoma (9,10). Such 
“experiments of nature” form the basis for the theory of cancer 
immunosurveillance, which proposes that a healthy immune 
system can protect an individual from the development and 
uncontrolled growth of malignancies (11). The theory of cancer 
immunoediting furthers the immunosurveillance theory and 
suggests that the immune system can both control the growth 
as well as shape the phenotype of cancer. It is thus possible that 
once a clinically evident tumor develops in an immunocompetent 
individual it has been sculpted to avoid immunorecognition, akin 
to bacterial drug resistance that develops in those treated with 
long-term antibiotics (12). Many studies in small animals with 
genetically engineered immune defects support observational 
human data and provide an experimental platform for studying 
the role of the tumor immune response.
Unfortunately few human or animal studies have focused on 
the role of the immune system in surveillance for lung cancer. 
Such lack of data leads to controversy in this field. A recently 
published European study of immunosuppressed patients 
demonstrated no increase in lung cancer in kidney or liver 
transplant recipients but an increase in those receiving a heart 
allograft (13). Based on this data it is possible to conclude that 
in the population as a whole immunosurveillance for lung cancer 
may not occur. Alternatively one could conceive that differences 
in cancer incidence may be unmasked only in patients with 
a significant smoking history, such as those requiring heart 
transplantation for coronary artery disease. Other observational 
studies, however, do not demonstrate an increase in lung cancer 
in heart transplant recipients, despite an increase in other 
cancers such as malignant melanoma and cervical carcinoma 
(14). Similar controversy exists in small animal models of lung 
cancer. Kobayashi and colleagues, for example, demonstrated 
that the incidence of chemically induced lung cancer is similar in 
immunocompetent and T cell deficient littermates while other 
investigators, using similar methodology, have demonstrated the 
importance of T cells in immunosurveillance for fibrosarcoma 
(15-17). Based on these and other data one must conclude 
that the existence of immunosurveillance for lung cancer is not 
rigorously supported by clinical or animal data. Thus, unlike 
clinical trials of immune based therapy for melanoma and renal 
cell carcinoma, the rationale for immunotherapy in the treatment 
of lung cancer deserves more background investigation. Since 
lung cancer, especially non small cell lung cancer (NSCLC), is 
the leading form of cancer related death (18,19), funding and 
execution of such trials is a critical priority to our field. 
History of tumor immunotherapy
The first organized trials of immunotherapy can be rightfully 
credited to a New York Surgeon William Coley, whose line 
of clinical research began in the 1890’s with an anecdotal 
observation that the facial sarcoma of a German immigrant, Fred 
Stein, miraculously regressed after a post-operative bacterial 
infection. This incident initiated Coley’s clinical research as he 
started to infect cancer patients with various bacterial isolates 
(20). Coley’s findings led to the creation of “Coley's toxin”, a 
concoction derived from cultures of Streptoccocus pyogens and 
Serratia marcasens (21). Only in the 1990’s was it defined that 
the anti-tumor effects of these bacterial toxins were the result 
of “tumor necrosis factor” produced by recipient macrophages 
rather then direct tumor toxicity (22). Multiple other strategies 
to stimulate an antitumor immune response have been similarly 
tried using bacterial products such as Corynebacterium parvum 
(23). The modern era of tumor immunotherapy can be traced to 
the use of adaptive cell therapy described in 1985 by Rosenberg 
and colleagues (24). In this classic translational trial, based 
directly on preclinical animal models, autologous lymphokine-
activated killer cells were administered along with recombinant 
interleukin-2 (IL-2) to patients with advanced cancer. Despite 
failure of all other therapy prior to entry into this trial, cancer 
regression was documented in 11 out of 25 patients. While the 
response of malignant melanoma was most striking, including 
one complete and long-lasting responder, tumor regression 
or stability was noted in other cancers as well, including 
one patient with lung cancer. Based on the overwhelming 
response documented in patients with metastatic melanoma, 
significant effort has focused on immunotherapy for this specific 
malignancy. Furthermore, the majority of clinical efforts in other 
types of malignancies are based on data generated from the 
melanoma model. 
Definition of tumor immunotherapy
Passive immunotherapy is defined as administration of an 
immunologically active agent to a patient that is made outside 
the body. In theory such a system does not rely on the function 
of the host’s own immune system to have its effect. Currently 
used examples of such therapy include the administration of 
monoclonal antibodies (25) or adaptive cell therapy, which 
is described below (26). Active immunotherapy focuses on 
stimulating the hosts own immune system to eradicate cancer, 
whether by vaccination with tumor antigens and an adjuvant, 
non specific immunomodulation using bacterial products, 
or targeting negative regulatory receptors that prevent the 
development of the tumor immune response. As described 
above some of the earliest trials and successes of immunotherapy 
involved active immunotherapy in the form of non-specific 
immunomodulation using bacterial products to stimulate the 
immune response. Despite the early success reported by Coley, 
others were unable to obtain a similar degree of success using 
Coley’s toxin (27). This resulted in the search for another form 
of immune stimulation. In 1908 Albert Calmette and Camille 
Guerin of the Pasteur Institute in Lille, France began work with 
the attenuated form of bovine tuberculosis, Mycobacterium 
bovis, or Bacille Calmette-Guérin (BCG), in an effort to develop 
a vaccine for human tuberculosis. Their work combined with the 
startling observation in 1929 by Raymond Pearl that patients 
with tuberculosis had a lower rate of cancer led to investigation 
into the use of live attenuated BCG as a form of tumor 
immunotherapy (28,29). To date BCG remains a clinically 
accepted and approved form of therapy for bladder cancer, with 
responses equal to if not superior to chemotherapy (30). 
Advances in understanding immune regulation have resulted 
in the development of more defined methods of stimulating 
the immune system. Based on the central role that IL-2 plays 
in orchestrating inflammatory responses, and its success in 
mediating regression of some forms of human cancer (24,31,32), 
it was approved for human use in 1992 for renal cell carcinoma 
and in 1998 for malignant melanoma. Recent work in elucidating 
pathways used by malignancies to downregulate the immune 
response has led to experimental and clinical success in the 
palliation of metastatic malignant melanoma (33). 
The administration of cancer vaccines, in the form of active 
immunotherapy, is based on the notion that malignancies 
express either mutated proteins that can be recognized as 
foreign antigens, overexpress normal proteins, or reexpress fetal 
antigens not present in the normal adult tissue. Such tumor 
associated antigens (TAA) form the basis for recognition of 
malignant tissue as a “foreign” entity (34,35). As a large number 
of such antigens can be presented to T lymphocytes by antigen-
presenting cells, a major effort has focused on immunizing 
cancer patients using either whole cells, proteins, or synthetic 
peptides in order to stimulate a tumor immune response. This 
form of active immunotherapy is also known as antigen-specific 
immunotherapy. Similar to other forms of immune based 
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therapy, the greatest success has been demonstrated in clinical 
trials for malignant melanoma, especially when combined with 
efforts to ameliorate pathways that downregulate the immune 
response. Cytotoxic T lymphocyte antigen-4 (CTLA-4) is 
receptor expressed on the surface of T cells that interacts with 
dendritic cell surface co-stimulatory molecules that then act 
to inhibit T cell activation (36). This interaction occurs in a 
competitive manner to the engagement of other T cell receptors, 
such as CD80 and CD86, which provide the signal necessary for 
the initiation of the T cell response. To this end the humanized 
form of anti-CTLA-4 IgG antibody (ipilimumab) was recently 
demonstrated to foster an anti-melanoma immune response 
leading to a significant survival advantage for patients with 
unresectable stage III or IV melanoma previously unresponsive 
to conventional therapy (33). Further encouraging results were 
reported in several large randomized clinical trials for prostate 
cancer, utilizing a vaccine targeting prostatic acid phosphatase 
(37,38), and follicular lymphoma using a vaccine unique for 
each individual patient (39).
Adoptive cell transfer is a form of passive immunotherapy that 
involves identification, isolation, expansion and subsequential 
re-infusion of autologous lymphocytes with anti-tumor activity 
into patients. This form of therapy has been used with or without 
administration of appropriate growth factors to enhance T cell 
survival and expansion in vivo. Such an approach also has the 
theoretic advantage that identification and isolation of only a few 
tumor reactive lymphocytes is sufficient for therapy as these cells 
can be expanded significantly in ex vivo prior to reinfusion (40). 
The genetic modification of isolated cells and the introduction of 
T cell receptors with high avidity for tumor specific antigens also 
creates exciting therapeutic possibilities (26).
Immunotherapy for lung cancer
Active immunotherapy for lung cancer can be traced back to 
observational studies suggesting that, similar to the sarcoma 
observations of Coley, local inflammatory changes may influence 
the prognosis of lung cancer (41,42). Enthusiasm for BCG 
therapy as adjuvant or neoadjuvant therapy was tempered early 
on by the lack of demonstrated efficacy in several clinical trials. 
While a 1981 series reported a decrease in local recurrence after 
adjuvant post-operative BCG in patients with early stage disease, 
these results may have been skewed by the high recurrence rate 
in the control group (43) and this data was not supported by 
further studies (44,45). Similarly disappointing results were 
noted for neoadjuvant therapy as Matthay and colleagues 
demonstrated that preoperative injection of BCG into NSCLC 
did not affect the disease-free interval or prolong survival (46). 
The discovery that, similar to malignant melanoma, NSCLC 
can express tumor associated antigens led to an ever increasing 
interest in the development of active immunotherapy protocols 
utilizing antigen specific immunotherapy. A few investigators 
have attempted to modify whole tumor cell vaccines to render 
them more immunogenic prior to patient administration in 
order to stimulate an anti-tumor immune response. The GVAX 
vaccine consists of autologous tumor cells engineered to express 
granulocyte monocyte colony stimulating factor (GM-CSF), 
which functions to enhance the production and migration 
of granulocytes such as neutrophils and monocytes with 
subsequential initiation of a tumor-specific immune response. 
Such treatment has been shown in animal models to increase 
the immunogenicity of certain tumors, especially malignant 
melanoma (47). Based on this data several early phase trials 
have been conducted using variable immunization protocols 
consisting of irradiated autologous NSCLC cells transduced with 
replication incompetent adenovirus expressing GM-CSF. One 
of the trials, reported in 2004, demonstrated encouraging results 
as three of the 33 patients with advanced disease had durable 
and complete responses, one patient had a minor response, and 
nine demonstrated a mixed response or disease stability (48). 
Interestingly a survival advantage was noted in patients receiving 
tumor vaccine secreting high levels of GM-CSF compared to 
those secreting lower levels. Based on this preliminary data other 
therapeutic strategies utilizing GVAX have been described (49).
Mucin-1 (MUC-1) is a protein normally expressed on 
secretory epithelial cells and is present in multiple epithelial 
cancers, including NSCLC (50). This mutated protein might 
be an ideal target for active immunotherapy as it is antigenically 
distinct from that found in normal tissue and functions as an 
oncogene (51,52). Based on this preliminary data a phase IIb 
study of patients with IIIa/IV stage lung cancer was conducted 
randomizing patients to immunization with a synthetic peptide 
designed to mimic the most antigenic portion of MUC-1 
(L-BLP-25), or best supportive care. Eight weekly injections 
were followed by maintenance immunization every 6 weeks 
after standard first line chemotherapy and a single dose of 
cyclophosphamide. Of the 171 patients in the trial those in the 
immunization arm demonstrated a trend towards longer median 
survival compared to the best supportive care group (17.4 vs. 13 
months) but this trend did not reach statistical significance (53). 
Such data, while limited, were encouraging and served as the 
foundation for a multicenter randomized double blind placebo 
control phase III trial in patients with unresectable stage III 
disease (START trial). 
MAGE-3 (melanoma associated antigen E-3) is a commonly 
expressed cancer testis antigen that is not present in normal 
adult tissue but is expressed on multiple malignancies including 
NSCLC (54). Like multiple other TAA it was initially identified 
in malignant melanoma based on its ability to stimulate 
autologous cytotoxic T lymphocytes (55). Aside from its 
restriction to extragonadal malignant tissue in the adult, MAGE-
3 is unique as this protein contains epitopes that can be presented 
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by both MHC Class I and MHC Class II histocompatibility 
antigens. Thus the ability of this TAA to activate both CD8+ and 
CD4+ cytotoxic T lymphocytes may offer a unique approach to 
stimulate a broad tumor-immune response using whole protein 
vaccination as a form of antigen specific immunotherapy (56, 
57). Based on these findings a phase II trial was performed 
randomizing patients with completely resected MAGE-3 positive 
stage IB and II NSCLC to either post-operative vaccination 
with recombinant MAGE-3 protein or placebo. When reported 
in 2007 a total of 30.6% patients in the vaccine arm and 43.3% 
in the placebo arm had recurred (58). While these differences 
did not reach statistical significance the data did suggest a trend 
of improved outcomes in the vaccination group and only few 
vaccine related side effects were recorded. Such reassuring data 
led to the implementation of a larger phase III trial adjuvant 
therapy trial, powered to detect differences in survival (5). The 
MAGRIT study (MAGE-A3 Adjuvant Non-Small Cell Lung 
Cancer Immunotherapy) is designed to enroll 2,270 MAGE-A3 
positive patients after anatomic resection of stage IB, II, or IIIA 
NSCLC. All patients will be randomized in a 2:1 fashion to 
receive either the vaccine or placebo with a clinical end point of 
disease free survival (59). 
Another very novel approach designed to harness the power 
of the immune system to treat lung cancer has been advanced 
by a group from Cuba. Clinical application of this approach is 
based on the finding that certain subsets of NSCLC express 
the epidermal growth factor (EGF) receptor and inhibition of 
this signaling pathway has been shown to have a therapeutic 
effect (60). The EGF vaccine is produced in the Center of 
Molecular Immunology in Havana, Cuba and is composed of 
recombinant EGF chemically conjugated to the P64 Neisseria 
meningitides recombinant protein adjuvant. The clinical 
efficacy of this vaccination strategy has been recently reported 
in a large randomized phase II trial (61). In this trial a total of 
eighty patients with stage IIIB/IV NSCLC were randomized 
to receive either vaccination or best supportive care after 
finishing first line chemotherapy. While few side effects were 
observed in the vaccinated group over half of the vaccinated 
patients demonstrated a good anti-EGF antibody response with 
a significant decrease in the serum EGF concentration. There 
was a trend for improved survival in the vaccination group that 
reached statistical significance in patients younger then 60 years 
of age. This very novel line of investigation offers the opportunity 
to target other cytokine or chemokine pathways responsible for 
growth and maintenance of lung cancer.
Multiple other trials targeting TAA in NSCLC, such 
as carcinoembryonic antigen (62) and HER-2/neu (63), 
have been described and are currently in clinical trials. 
W hile recent dramatic success with adoptive cell therapy 
has been demonstrated for malignant melanoma (26) such 
strategy has not yet been adapted to the field of lung cancer 
immunotherapy due to the lack of a well-defined and established 
immunodominant tumor antigen. Perhaps success in clinical 
trials using vaccination with defined peptides or whole proteins 
will pave the way for adoptive cell therapy in the future.
Unlike NSCLC, small-cell lung cancer (SCLC) represents 
only 15-20% of all primary malignancies the lung. SCLC is 
usually a systemic disease at the time of diagnosis and only 
anecdotal long-term survival has been reported. Even limited 
disease, although initially responsive to chemo and radiation 
therapy, often recurs (64,65). Based on these reasons biologic 
therapy, such as immunotherapy, that can offer a long-term 
tumor-specific response may be an ideal treatment modality for 
this malignancy. Gangliosides are glycolipid components of the 
plasma membrane that play an integral role in multiple biologic 
functions. Compared to the normal cellular components of 
the lung, neutral glycolipids are more prevalent in SCLC (66). 
While poorly immunogenic in and of themselves, these antigens 
can be successfully targeted by anti-idiotypic antibodies. 
This form of immunotherapy takes advantage of the fact that 
“secondary” antibodies raised against a primary antibody to a 
defined antigen, even one of low affinity, will mimic epitopes 
present in the original antigen in the hypervariable region of 
the immunoglobulin. Administration of such anti-idiotypic 
antibodies can then be used to generate both a humeral and 
cellular TAA-specific immune response as the antibody itself acts 
as an antigen (67,68). GD3 is a ganglioside present in tumors of 
neuroectodermal origin including small cell lung cancer. While 
itself poorly immunogenic (69), the anti-idiotype antibody to 
this antigen (Bec2) produces a detectable anti-GD3 immune 
response in as many as one-third of the treated patients (70,71). 
A small pilot study of Bec2 vaccination combined with BCG 
performed at Memorial Sloan-Kettering Cancer Center, revealed 
a surprisingly positive response in the 15 treated patients and 
acted as a nidus for a large randomized prospective trial (72). 
Such a study was performed between 1998 and 2002 as 515 
patients from 120 institutions in 17 countries with limited SCLC 
were prospectively randomized to receive either vaccination with 
Bec2 and a BCG adjuvant or observation alone after completing 
induction chemoradiotherapy. When published in 2005 the 
investigators were unable to detect an improvement in overall 
survival, progression-free survival, or quality of life in those 
in the vaccination arm (4). While a trend towards prolonged 
survival was detected in the one third of patients who developed 
a detectable humoral immune response to the vaccination, this 
did not reach statistical significance. Toxicity was mostly related 
to local skin-site irritation with occasional systemic effects 
such as lethargy, arthralgia, and myalgia. Thus while this Bec2 
vaccination trial presented an overall negative result the potential 
for vaccination and immune-based therapy as an adjuvant 
method for treating SCLC remains a future possibility if vaccines 
capable of producing a better immunologic response can be 
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developed. 
Limitations and future directions
Immune based therapy for the treatment of solid cancer remains 
an exciting approach that is quickly making headway from the 
laboratory to the clinic. A cautionary and rational approach 
needs to be taken, however, in order to prevent negative results 
from halting progression of this field. First of all the potential for 
autoimmune disease resulting from successful immunotherapy 
of what is essentially altered self requires a cautious approach 
to clinical experimentation. Even with current therapy 
autoimmune vitiligo is often a complication of immunotherapy 
for malignant melanoma and the use of allogenic bone marrow 
transplantation as a mechanism of immunotherapy for leukemia 
is often complicated by graft vs. host disease (73-75). Lessons 
learned from notable examples such as the National Emphysema 
Treatment Trial of lung volume reduction surgery, or the 
recent human gene therapy trial for ornithine transcarbamylase 
deficiency complicated by a patient death, demonstrate that 
patient selection is critical for maintaining public enthusiasm and 
support for clinical trials (76-78). Second of all it is important to 
note that multiple current trials of immune based therapy enroll 
patients with residual bulky primary or metastatic disease. Such 
a strategy is counterintuitive to data demonstrating that tumor 
volume directly impacts the ability to mount a successful tumor-
specific immune response (79) . It also goes against experimental 
data, from out laboratory as well as others, which demonstrate 
that tumor associated stromal cells, both radiosensitive 
hematopoietic myeloid cells and radioresistant endothelial cells, 
can influence the tumor immune response (80-82). Thus a 
potential therapeutic approach might combine immunotherapy 
with complete gross tumor resection or aggressive debulking in 
order to target minimal residual disease in the adjuvant setting. 
Patient enrollment in the MAGRIT trial described above, for 
example, is limited only to those with completely resected 
disease, thus avoiding the immunologic barriers imposed by a 
bulky tumor mass (58,59). 
Summary
Unlike the case for malignant melanoma, immunotherapy 
for NSCLC lags behind in both experimental and clinical 
development. In fact most clinical trials are based on successful 
therapy defined in preclinical models for malignant melanoma. 
It is possible, however, that lung cancer may not respond to 
similar immunotherapy strategies. Since the lung is a naturally 
tolerogenic organ and intratracheal instillation of antigen is 
a successful and accepted method for induction of tolerance 
(83), it is possible that lung cancer directed immunotherapy 
needs to be routinely combined with strategies to downregulate 
mechanisms of tolerance induction (33). It is also possible that 
tumor immunoediting, or the elimination of immunodominant 
antigens by the immune system, is highly prevalent in lung 
cancer, resulting in resistance to immunotherapy (12). It is 
however, not inconceivable that lung cancer develops completely 
independent of immunologic influences and remains completely 
invisible to the immune system. If this were to be the case other 
strategies, such as targeted therapy of growth factor receptors, 
might be necessary for adjuvant treatment of lung cancer instead 
of immunotherapy (60).
Inbred mice offer an efficient and reproducible method 
to study carcinogen-induced lung cancer as a highly reliable 
model of lung adenocarcinoma exists. A single injection of 
urethane leads to the development of early adenomatous 
tumors in the lung within 10 weeks with progression to fully 
invasive adenocarcinoma after 32 weeks (84). The progression 
of such cancers from hyperplasia to benign adenoma to fully 
invasive adenocarcinoma with metastatic potential mimics 
progression of human disease. Interestingly multiple studies 
have defined different strains of mice as either tumor-susceptible 
“high-responders” (A/J for example) or tumor resistant “low 
responders” (C3H He/J for example) with 100% of susceptible 
animals and few resistant ones developing tumors after injection 
of carcinogen (85). This variability in strain susceptibility to 
induction of lung adenocarcinoma suggests that inherent genetic 
factors may alter the development and/or progression of NSCLC 
independent of carcinogen administration or the environment 
(85). The use of such models to develop a better understanding 
of lung cancer immunology and immune evasion, as has been 
done for malignant melanoma, might facilitate a more rational 
approach toward lung cancer immunotherapy.
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